Asset profile

Nab-paclitaxel

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HR+/HER2- Metastatic Breast Cancer, Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(67 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (9)

September 2026 (1)

Phase 2Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8 …Recruiting

Est. primary completion 2026-09-30 · NCT04892953 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (2)

Phase 2Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxelRecruiting

Est. primary completion 2026-10-20 · NCT04138719 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-10-31 · NCT05852691 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2026-11 · NCT06704620 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)

Phase 2Triple-negative Breast Cancer, Bone MetastasesRecruiting

Est. primary completion 2026-12 · NCT06538896 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting

Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2026-12-15 · NCT07245797 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2026-12-17 · NCT06747169 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (19)

February 2027 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2027-02-12 · NCT06492759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (1)

Phase 2HER2-positive Breast CancerNot yet recruiting

Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (3)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-06 · NCT06922591 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)

Phase 3Triple Negative Breast Cancer(TNBC)Active not recruiting

Est. primary completion 2027-07 · NCT06419621 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 1/2Advanced Solid Tumors, HER2-positive Breast CancerActive not recruiting

Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)

Phase 2TNBC, Triple Negative Breast CancerRecruiting

Est. primary completion 2027-09-15 · NCT07601178 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (2)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-10-31 · NCT06604351 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-10-31 · NCT04266249 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (7)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast Cancer MetastaticRecruiting

Est. primary completion 2027-12 · NCT05582538 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-01 · NCT07200947 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Triple Negative Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT07281976 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT06964906 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Advanced Triple Negative Breast CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-31 · NCT07662811 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (15)

January 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-01-31 · NCT07284836 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (3)

Phase 3Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast CancerRecruiting

Est. primary completion 2028-03-13 · NCT06876714 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple-negative Breast CancerRecruiting

Est. primary completion 2028-03-22 · NCT07045311 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-03-31 · NCT06860529 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (3)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-06 · NCT05786924 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, HER2-positive Breast CancerRecruiting

Est. primary completion 2028-06 · NCT06441890 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-06 · NCT05502237 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting

Est. primary completion 2028-07-30 · NCT07752550 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 2Solid TumorsRecruiting

Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)

Phase 2Metastatic Squamous Non-Small Cell Lung CarcinomaRecruiting

Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting

Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (3)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-12-07 · NCT07193394 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HER2-positive Early Breast CancerRecruiting

Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (10)

January 2029 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2029 (1)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-05-01 · NCT07527806 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (2)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (3)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-12 · NCT07173751 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-12-31 · NCT07565324 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-12-31 · NCT07772245 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (7)

January 2030 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-01 · NCT06745882 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Double BlindRecruiting

Est. primary completion 2030-01-24 · NCT07662395 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2030 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2030 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2030-11-01 · NCT06109402 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-12-31 · NCT05981014 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (4)

January 2031 (1)

Phase 2/3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2031 (1)

Phase 2/3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2031 (1)

Phase 3Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8Recruiting

Est. primary completion 2031-10-15 · NCT05624996 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2031 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2031-12-01 · NCT06837948 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)

April 2032 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (2)

January 2035 (1)

Phase 3Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Recruiting

Est. primary completion 2035-01-31 · NCT06096844 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2035 (1)

Phase 2/3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2035-12-31 · NCT07365319 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.